Published: April 8, 2026
Here is the scenario that should concern every dietary supplement manufacturer: your product ships nationwide, your label has been through your standard review process, and then — through routine internal testing — you discover it contains three undeclared major food allergens. Egg. Hazelnut. Soy. Three simultaneous allergen failures in a single product.
That is exactly what happened to Blueroot Health in March 2026 with their Vital Nutrients Aller-C dietary supplement. And while the company's internal testing deserves credit for catching the problem before it caused a documented injury, the recall exposes a compliance vulnerability that is far more common than the industry acknowledges: allergen hazards in dietary supplements are systematically undercontrolled compared to conventional food manufacturing.
The regulatory stakes are clear. Under the Food Allergen Labeling and Consumer Protection Act of 2004 (FALCPA), dietary supplements are not exempt from allergen labeling requirements. A capsule with undeclared egg, hazelnut, or soy is misbranded under Section 403(w) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) — the same statutory violation that applies to a mislabeled bag of peanuts. The fact that the product is a supplement, not a snack food, changes nothing about the legal exposure.
This article breaks down the Blueroot/Vital Nutrients Aller-C recall, the regulatory framework that governs it, and — most critically — the manufacturing and labeling controls every supplement company should have in place today to avoid the same outcome.
The Recall: What Happened
On March 27, 2026, Blueroot Health of Middletown, Connecticut issued a voluntary allergy alert on specific lots of Vital Nutrients Aller-C Dietary Supplement (capsule form) due to the presence of undeclared egg, hazelnut (a tree nut), and soy. The company discovered the undeclared allergens through routine internal testing — a detail that matters considerably, as it represents the best-case scenario for this type of failure.
The affected lots are as follows:
| Package Size | Lot Number(s) | UPC | Expiration |
|---|---|---|---|
| 200-capsule bottle | 25E04-B | 693465524213 / 693465000090 | 05/27 |
| 100-capsule bottle | 25E04-A and 25E04-B | 693465524114 / 693465000083 | 05/27 |
Distribution was nationwide, through VitalNutrients.co and other online retailers. As of the recall announcement, no illnesses or adverse reactions had been reported. Consumers who purchased affected products are instructed to stop use immediately and return the product to Blueroot Health for a replacement. Consumer contact information: (888) 328-9992, Monday through Friday, 8am–7pm ET, or [email protected].
The full FDA recall notice is available on the FDA website.
Why This Recall Matters: The Regulatory Stakes
Undeclared allergens are not a labeling technicality. They are a life-safety hazard. According to the Food Allergy Research and Education organization (FARE), more than 33 million Americans live with food allergies — including approximately 5.6 million children. A person with an egg or tree nut allergy who unknowingly consumes an affected Vital Nutrients Aller-C capsule faces the risk of a serious or life-threatening anaphylactic reaction. Undeclared allergens are consistently one of the top causes of FDA food and supplement recalls year after year.
The statutory framework is unambiguous. FALCPA, effective January 1, 2006, requires that all major food allergens be declared on food labels — and dietary supplements are expressly covered by this requirement. Under Section 403(w) of the FD&C Act, a food product (including a dietary supplement) that contains a major food allergen not properly declared on its label is legally misbranded. A misbranded product cannot lawfully be introduced into interstate commerce. That means the moment an affected lot of Aller-C left the facility without declaring egg, hazelnut, and soy, it was in violation of federal law.
The FASTER Act of 2021 (Food Allergy Safety, Treatment, Education, and Research Act) expanded the list of major food allergens from eight to nine by adding sesame, effective January 1, 2023. The nine major food allergens now required to be declared on all food and supplement labels are: milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans, and sesame.
Three of those nine allergens appeared undeclared in a single lot of Vital Nutrients Aller-C. That is not a narrow edge case — it signals systemic gaps in allergen controls that most supplement manufacturers share to some degree.
Three Allergens, Three Compliance Failures
Each of the three undeclared allergens in this recall has distinct labeling mechanics under FALCPA and FDA regulations. Understanding the specific requirements for each allergen is essential for building a compliant label and an effective allergen control program.
Egg
Eggs are one of the original eight major food allergens recognized under FALCPA. Proper disclosure requires that "egg" appear either parenthetically in the ingredient list — for example, "albumin (egg)" — or in a "Contains" statement immediately following the ingredient list: "Contains: Egg." For dietary supplements specifically, the allergen declaration is permitted within the Supplement Facts box or in the "Other Ingredients" section, as long as the disclosure is clear and proximate to the ingredient list. An egg-derived ingredient without a parenthetical or "Contains" declaration renders the label non-compliant.
Hazelnut (Tree Nut)
This is the most technically demanding of the three failures. Tree nuts are a major food allergen category, but FALCPA — and FDA's implementing guidance — requires that the specific type of tree nut be declared on the label. It is not sufficient to write "tree nut." The label must specify "hazelnut." This specificity requirement exists because tree nut allergies can be species-specific: a consumer allergic to hazelnuts may not be allergic to almonds or cashews, and vice versa. FDA's January 6, 2025 updated guidance, "Questions and Answers Regarding Food Allergens, Including the Food Allergen Labeling Requirements of the Federal Food, Drug, and Cosmetic Act (Edition 5)," addresses this directly and reinforces that a generic "tree nut" declaration is not an acceptable substitute for the specific variety.
A "Contains: Tree Nut" statement would be legally insufficient. The correct declaration is "Contains: Hazelnut" or, within the ingredient list, a parenthetical such as "(hazelnut)" following the relevant ingredient.
Soy (Soybeans)
Soy is one of the most commonly encountered undeclared allergens in dietary supplements because soy derivatives appear in a wide range of excipients, capsule coatings, lecithins used as emulsifiers, and processing aids. A supplement manufacturer can have soy enter the finished product without it appearing in the master formula if a supplier changes a non-primary ingredient without notification. Proper declaration requires "soy" or "soybeans" to be named either parenthetically in the ingredient list or in a "Contains" statement. As with egg and hazelnut, this requirement applies equally to the Supplement Facts panel and the Other Ingredients section for dietary supplement products.
How Undeclared Allergens Enter Supplements: The Manufacturing Reality
Three undeclared allergens in a single product lot is unusual in its scope, but not in its mechanism. Having worked with dietary supplement manufacturers across a wide range of product categories, I've seen the same failure modes repeat across the industry. Understanding how allergens enter supplement products — and why existing controls fail to catch them — is the foundation of prevention.
Shared Equipment and Cross-Contact
Many supplement contract manufacturers run dozens of different product formulations on the same blending, encapsulation, and bottling equipment. Even with cleaning between runs, equipment that has contacted egg-derived ingredients, hazelnut powder, or soy lecithin can transfer residual allergens to the next product on the line. If cleaning validation has not been performed to demonstrate allergen removal — not just visual cleanliness — the next batch is at risk of cross-contact contamination that will never appear on its label.
Ingredient Substitution Without Change Control
Supplement formulas contain active ingredients, but they also contain excipients: fillers, flow agents, lubricants, coatings, and capsule materials. These excipients are frequently sourced from multiple suppliers and can change without triggering a formal change control review. A magnesium stearate supplier, for example, might shift their manufacturing process in a way that introduces soy as a processing aid. If the supplier does not notify the supplement manufacturer, and if the supplement manufacturer's supplier verification program does not include allergen-specific Certificate of Analysis (CoA) review, the allergen enters the product undetected.
Mislabeled or Misidentified Raw Materials
Bulk ingredient suppliers — particularly for botanical extracts and nutritional powders — occasionally mislabel or misidentify raw materials during packaging. A quercetin powder adulterated with a hazelnut-derived extract, or a vitamin C complex that includes a bioflavonoid fraction derived from egg, would not be apparent from the ingredient declaration on the raw material container if the container itself is mislabeled. Without incoming testing to verify identity and allergen status, mislabeled raw materials pass directly into production.
Bulk Ingredient Commingling
In warehouse environments where bulk ingredients are stored across multiple products, physical proximity can create allergen transfer risks. Soy-containing powders stored adjacent to allergen-free ingredients, or shared scoops used across different ingredient bins, represent cross-contact pathways that are difficult to detect after the fact and must be controlled through physical segregation protocols and dedicated utensil programs.
Label Updates That Lag Behind Formula Changes
A supplement company revises its formula — perhaps adding a new excipient or switching raw material suppliers — and the quality team processes the change. But the label update request gets delayed, submitted to the wrong queue, or flagged for design revision rather than compliance review. The new formula ships under the old label. This is one of the most preventable failure modes, and one of the most common.
What 21 CFR Part 117 Requires You to Do
The allergen failures in the Blueroot/Vital Nutrients Aller-C recall are not just FALCPA violations — they are likely also failures under 21 CFR Part 117, FDA's Current Good Manufacturing Practice and Preventive Controls for Human Food regulation. Dietary supplement manufacturers are subject to 21 CFR Part 111 for supplement-specific GMPs, but are also covered by Part 117's preventive controls framework for food safety hazards, including allergens.
Under 21 CFR Part 117, manufacturers must conduct a hazard analysis that explicitly considers allergen hazards — both undeclared allergens due to labeling failures and allergen cross-contact. Where allergen hazards are identified as requiring a preventive control, the facility must implement, monitor, and verify those controls.
Written Allergen Preventive Controls
Under 21 CFR § 117.135(c)(2), allergen controls are a required category of preventive controls in the Food Safety Plan. These must be documented in writing and must address both labeling controls (ensuring allergens are properly declared) and allergen cross-contact controls (preventing unintended allergen transfer during processing).
Label Verification as a Preventive Control
FDA's allergen preventive controls framework treats label verification as a critical control point. Before a product is distributed, the finished product label must be verified against the master formula to confirm that all allergens present — whether in active ingredients, excipients, or processing aids — are properly declared. This verification must be documented and must be performed by, or supervised by, a Preventive Controls Qualified Individual (PCQI).
Allergen-Specific Cleaning Validation
Where shared equipment is used across allergen-containing and allergen-free products, cleaning procedures must be validated to demonstrate that allergens are reduced to acceptable levels before the next product run. Visual inspection alone is insufficient — analytical testing using allergen-specific ELISA or lateral flow assays is the industry standard for cleaning validation in allergen control programs.
Supplier Qualification for Allergen Status
Under 21 CFR §§ 117.410–117.475 (Supply Chain Program), supplement manufacturers must verify that their ingredient suppliers control allergen hazards in the materials they provide. This includes obtaining allergen declarations and CoAs for every ingredient at each lot receipt, requiring written supplier notification of any formulation or processing changes, and conducting periodic audits or reviewing third-party audit results for high-risk suppliers.
Monitoring, Corrective Actions, and Verification
Allergen preventive controls must be monitored at defined intervals (21 CFR § 117.140), corrective actions must be documented when controls fail (21 CFR § 117.150), and the overall effectiveness of allergen controls must be verified — including through environmental and finished product testing where appropriate (21 CFR § 117.155). These are not aspirational practices; they are regulatory requirements with documentation that FDA expects to review during an inspection.
FDA's January 2025 Guidance Update: What Changed
On January 6, 2025, FDA published Edition 5 of its guidance document "Questions and Answers Regarding Food Allergens, Including the Food Allergen Labeling Requirements of the Federal Food, Drug, and Cosmetic Act." This update is directly relevant to dietary supplement manufacturers and clarifies several compliance areas that were previously ambiguous.
For dietary supplements specifically, Edition 5 confirms that allergen declarations are required and may appear within the Supplement Facts box or in the Other Ingredients section — but must be clear, proximate, and consistent with FALCPA's formatting requirements. FDA addressed scenarios involving highly refined ingredients (such as highly refined oils, which are generally exempt from allergen declaration under FALCPA) and clarified that the exemption applies narrowly and does not extend to most soy or egg derivatives found in supplement excipients.
On tree nuts, Edition 5 reinforces the specificity requirement: the specific type of tree nut must be declared, not merely the allergen category. This is particularly relevant for supplement manufacturers who source complex botanical extracts or bioflavonoid complexes that may contain hazelnut-derived fractions — and who may have assumed that a generic "tree nut" declaration was acceptable. It is not.
The guidance also updated the discussion of sesame, which became the ninth major allergen on January 1, 2023 under the FASTER Act. Supplement manufacturers who use sesame oil, sesame seed extracts, or sesame-derived excipients must declare sesame on their labels, and must evaluate their facilities for sesame cross-contact risks as part of their allergen preventive controls hazard analysis. Manufacturers who have not yet updated their allergen programs to include sesame are behind on a compliance requirement that has been in effect for over three years.
See our FDA Dietary Supplement Labeling Compliance Guide for a comprehensive breakdown of label requirements across the Supplement Facts panel, structure-function claims, and allergen declaration formatting.
The Enforcement Escalation Path
Blueroot Health caught this problem through internal testing. That is the critical fact in this story. It means the company initiated a voluntary recall before FDA discovered the violation through an inspection, a consumer complaint, or a third-party adverse event report. Voluntary recalls — while costly and reputationally disruptive — represent the best outcome available once an allergen labeling failure occurs.
What happens when internal testing does not catch the problem? FDA's enforcement escalation path for undeclared allergen violations follows a predictable sequence.
A consumer adverse event report or retailer complaint triggers an FDA investigation. The agency reviews the product label against the actual formulation and confirms the misbranding violation under Section 403(w) of the FD&C Act. At this point, FDA will typically issue a mandatory recall request if the company has not already acted voluntarily. The company faces the same product recovery costs and consumer notification obligations — but under FDA directive rather than on its own terms.
If FDA determines that the allergen failure reflects systemic deficiencies in the company's manufacturing or quality systems, the agency can issue a Warning Letter citing violations of 21 CFR Part 117 in addition to the FALCPA misbranding finding. A Warning Letter creates a public record, affects the company's FDA establishment inspection profile, and triggers follow-up inspections. For a supplement company selling through major retail channels, a public Warning Letter often results in delisted products and lost distribution agreements that far exceed the direct cost of the recall itself.
In cases where a company fails to respond adequately to a Warning Letter, or where allergen failures have caused consumer injury, FDA can pursue injunctive relief — a federal court order requiring the company to cease manufacturing — or seek seizure of adulterated and misbranded inventory. Criminal prosecution, while less common, has been applied in cases involving willful violations or repeated non-compliance after warning.
The Blueroot recall demonstrates that internal testing works. The enforcement escalation path demonstrates what happens when it does not.
Practical Compliance Checklist for Supplement Manufacturers
The following action items represent the core of an allergen control program that will withstand both FDA inspection and the real-world manufacturing conditions that generate allergen failures.
- Conduct a full allergen inventory of every ingredient in every product. This includes active ingredients, excipients, processing aids, and capsule or coating materials. Map each ingredient back to its supplier's most recent allergen declaration and CoA.
- Verify every finished product label against the current master formula. This verification must be documented, must occur before any new lot is released for distribution, and must be repeated whenever the formula or any ingredient supplier changes.
- Review all CoAs for allergen status at every lot receipt. Do not rely on historical supplier declarations — allergen status must be confirmed lot by lot, particularly for excipients and botanical extracts that may be sourced from multiple origins.
- Require written notification from suppliers before any formulation or processing change. A supplier change control requirement embedded in your supplier qualification agreement is the only way to ensure you receive advance notice of allergen-relevant ingredient modifications.
- Validate cleaning procedures for allergen removal on shared equipment. Cleaning validation must include analytical testing — not just visual inspection — using ELISA or lateral flow assays for the allergens in question. Validation must be repeated if cleaning procedures or equipment change.
- Update your allergen hazard analysis to include sesame. If your facility uses any sesame-derived ingredient or if sesame is processed in your contract manufacturer's facility on shared equipment, sesame must be addressed in your allergen preventive controls documentation.
- Perform periodic third-party finished product testing for allergens. Internal testing — as demonstrated by the Blueroot recall — is your last line of defense. Third-party testing provides an independent verification layer and is essential for high-risk products or product categories with complex ingredient profiles.
- Conduct periodic audits of contract manufacturers. If your product is manufactured by a contract manufacturer, your allergen control program extends into their facility. Audit their allergen controls, review their cleaning validation data, and verify that your product is not scheduled on shared lines with allergen-containing products without adequate separation controls.
- Document everything. FDA inspectors reviewing allergen controls will request written procedures, monitoring records, corrective action documentation, verification records, and supplier qualification files. If the control was not documented, it did not happen from a regulatory standpoint.
- Review your recall plan annually. The Blueroot recall demonstrates that even companies with internal testing programs reach the point of needing to execute a recall. Your recall plan should be current, tested, and include customer notification lists organized by lot code, FDA district office contact information, and documented procedures for product recovery and disposition.
What Consumers Should Do Right Now
If you have purchased Vital Nutrients Aller-C Dietary Supplement, check your product against the affected lot numbers listed above. The affected lots are:
- 200-capsule bottles: Lot 25E04-B (UPC 693465524213 or 693465000090)
- 100-capsule bottles: Lots 25E04-A or 25E04-B (UPC 693465524114 or 693465000083)
- Expiration date on all affected lots: 05/27
If you have one of the affected lots and you have an allergy or severe sensitivity to egg, hazelnut, or soy, do not consume the product. Stop use immediately. Contact Blueroot Health at (888) 328-9992 (Monday through Friday, 8am–7pm ET) or by email at [email protected] to arrange for a product replacement. If you have already consumed the product and are experiencing symptoms of an allergic reaction — including hives, swelling, difficulty breathing, or anaphylaxis — seek emergency medical care immediately and report the reaction to FDA's MedWatch program at FDA.gov/medwatch.
Conclusion: Internal Testing Saved Blueroot From a Worse Outcome
The March 27, 2026 Blueroot Health voluntary allergy alert on Vital Nutrients Aller-C is a textbook example of a recall that went as well as it possibly could, given that the underlying compliance failures were already made. Three undeclared allergens in a single product lot is a serious violation of FALCPA and Section 403(w) of the FD&C Act. But the company's internal testing program caught the problem before it produced a documented consumer injury, before FDA identified it through inspection or complaint, and before the company was forced to act under agency direction rather than its own initiative.
That outcome is not accidental. It reflects a testing infrastructure that most small and mid-size supplement companies do not have. And it raises the most important compliance question every supplement manufacturer should be asking right now: would your process catch this before a consumer does?
The answer requires more than good intentions. It requires a documented allergen hazard analysis under 21 CFR Part 117, written allergen preventive controls with monitoring and verification, validated cleaning procedures on shared equipment, lot-by-lot CoA review from ingredient suppliers, and periodic finished product testing against the full allergen panel. It requires treating allergen control not as a labeling function, but as a manufacturing risk management system.
If your supplement company has not recently reviewed its allergen preventive controls against current FDA requirements — including the sesame additions under the FASTER Act and the clarifications in FDA's January 2025 Edition 5 guidance — the Blueroot recall is your signal to do so now. The regulatory framework is clear, the enforcement consequences are serious, and the cost of catching this problem internally is always lower than the cost of a consumer injury or an FDA-directed recall.
If you need expert guidance on building or auditing your allergen control program, contact Certify Consulting for a confidential consultation.
Last updated: April 8, 2026
Jared Clark
FDA Compliance & Regulatory Affairs Consultant
Jared Clark is the founder of Certify Consulting and helps dietary supplement manufacturers, food companies, and life sciences organizations achieve and maintain compliance with FDA regulations and international standards.